Abstract: A photovoltaic device is presented. The photovoltaic device includes a layer stack; and an absorber layer is disposed on the layer stack. The absorber layer comprises selenium, wherein an atomic concentration of selenium varies across a thickness of the absorber layer. The photovoltaic device is substantially free of a cadmium sulfide layer.

Abstract: A mounting assembly for mounting a mounting foot to a base pan comprises a grommet, a mounting foot and a fastener. The grommet includes a body, an upper post and a lower post. The upper post extends from a first end the body and the lower post extends from a second end of the body. The upper post has a shoulder. The mounting foot has a mount opening for receiving the upper post. The mount opening has a diameter. The fastener is received on the upper post, and maintains the mounting foot on the upper post. The mounting foot has a thickness less than the thickness of the shoulder.

Abstract: A mounting device mounts a mounting foot to another member, such as a base pan. The mounting device includes a grommet, a splined washer and a fastener. The grommet has an axially extending post for receiving a mounting foot. The splined washer is configured to lock into the mounting foot and the post. The splined washer has an inner bore for receiving the post. The fastener is received on the post and maintains the splined washer and the mounting foot on the post.

Abstract: A mounting feature secures a grommet to a compressor foot of a compressor. A compressor foot includes a hole and a slot extending between an outer perimeter of the compressor foot and the hole to receive a portion of a grommet. The slot is defined by a first wall and an opposing second wall, and at least one of the first wall and the opposing second wall includes a projection that extends into the slot.

Abstract: Peptide analogues are provided with amino acid sequences of the corticotropin-releasing factor superfamily, but having at least one amino acid residue that has been replaced with a D-amino acid residue or a D-amino acid analog. The peptide analogues have anti-inflammatory activity while having a receptor selectivity and thus a disassociated ACTH response.

Abstract: A method for treating inflammatory conditions is provided in which a peptide is administered in an amount effective to decrease inflammation, with the peptide having the sequenceG-G-F-L-R-R-I-R-P-K-L-K-W-D-N-Q (SEQ ID NO:1),G-G-F-L-R-R-I-R-P-K-L-K-W-D-N-Q-NH.sub.2 (SEQ ID NO:2),Ac-R-R-I-R-P-K-L-NH.sub.2 (SEQ ID NO:3), orAc-R-R-I-R-P-K-l-NH.sub.2.

Abstract: Small, anti-inflammatory compounds that are peptide analogs are described useful to inhibit inflammation of a mammal's skin, mucous membranes, or lacerations of the musculature or injury to the brain or leakage of fluids into the air spaces of the lungs. Peptide analogs of the invention have the primary sequence T.sub.N -A.sub.1 -A.sub.2 -A.sub.3 -A.sub.4 -A.sub.5 -A.sub.6 -T.sub.C where one of the moieties is in the D-configuration. A.sub.1 and A.sub.2 are each a basic polar amino acids while each of A.sub.3, A.sub.4, and A.sub.6 is a hydrophobic amino acid. A.sub.5 can be a variety of structures and appears to function to optimize the spatial relationship between the hydrophobic and the basic residues. T.sub.N is selected or modified to convey resistance against enzymatic degradation. T.sub.C is an amino group or an amidated amino acid, preferably hydrophobic.